Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | MMP3 | P08254 | 1/20 | 0.35 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13429705 | 0.90 | MEN1 (0.56) | MEN1KMT2AMMP3LIPGJAK3 | |
| SCHEMBL10198621 | 0.71 | HTR7 (0.47) | MAP4K4 | |
| SCHEMBL8904029 | 0.70 | MEN1 (0.70) | MEN1KMT2AMMP3LIPG | |
| SCHEMBL11383993 | 0.70 | MEN1 (0.50) | MEN1KMT2A | |
| SCHEMBL21591 | 0.69 | HTR7 (0.39) | MAP4K4 | |
| SCHEMBL8337927 | 0.68 | MEN1 (0.61) | MEN1KMT2AMMP3 | |
| SCHEMBL31083635 | 0.68 | PRKCI (0.51) | MAP4K4 | |
| SCHEMBL10198629 | 0.68 | TAAR1 (0.44) | — | |
| SCHEMBL12401870 | 0.65 | MEN1 (0.41) | MEN1KMT2A | |
| SCHEMBL31377009 | 0.65 | MEN1 (0.59) | MEN1KMT2AMMP3JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150072997-A1 | ANTI-MALARIAL COMPOUNDS | POLYMEDIX, INC. | 2015-03-12 | — | — | US | disclosed |
| US-8796275-B2 | Anti-malarial compounds | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2014-08-05 | — | — | US | disclosed |
| US-20100081665-A1 | Anti-Malarial Compounds | CELLCEUTIX CORPORATION | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081665-A1 | Anti-Malarial Compounds | AADAC, ME2, HTRA2 | MEN1 4052/4885KMT2A 476/4885MMP3 1413/4885 |
| US-20150072997-A1 | ANTI-MALARIAL COMPOUNDS | AADAC, ME2, HTRA2 | MEN1 4052/4885KMT2A 476/4885MMP3 1413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.